Martin Reck

17PUBLICATIONS
103CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jul 30, 2026
Combined circulating tumor antigen model demonstrates additional prognostic value in first-line treatment of non-small cell lung cancer.

|Jul 01, 2026
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.

|Jun 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.

|Apr 10, 2026
First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study.

Jhanelle E Gray, Joel W Neal, Jyoti D Patel

|Dec 13, 2025
Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design.

Martin Reck, Shun Lu, Kenneth J O'Byrne

|Dec 03, 2025
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.

Tianshi Lu, Habib Hamidi, Mark A Socinski

Pageof 3

Frequent Collaborators

4 joint publications

Lizza E L Hendriks

2 joint publications

John V Heymach

2 joint publications

Edward B Garon

2 joint publications

Makoto Nishio